A Comparison of Clinicopathological Features and Molecular Markers in British and Nigerian Women with Breast Cancer
2008

Breast Cancer Differences Between British and Nigerian Women

Sample size: 68 publication Evidence: moderate

Author Information

Author(s): Gukas Isaac D., Girling Anne C., Mandong Barnabas M., Prime Wendy, Jennings Barbara A., Leinster Samuel J.

Primary Institution: University of East Anglia

Hypothesis

Are there differences in tumor biology between British and Nigerian women with breast cancer?

Conclusion

Nigerian women with breast cancer have lower estrogen receptor expression and present at a later clinical stage, which may lead to poorer outcomes compared to British women.

Supporting Evidence

  • Significant differences in ER and CCND1 expression were found between the two cohorts.
  • Nigerian women presented with higher clinical stages of breast cancer compared to British women.
  • Lower hormone receptor levels in Nigerian women predict poorer response to hormonal therapy.

Takeaway

This study found that breast cancer is more aggressive in Nigerian women compared to British women, with lower hormone receptor levels and later stage at diagnosis.

Methodology

The study compared tumor characteristics and molecular markers in breast cancer biopsies from age-matched cohorts of Nigerian and British women.

Potential Biases

Potential bias due to differences in healthcare access and diagnostic practices between the two countries.

Limitations

Pathological staging was not routinely performed in Nigeria, which may affect the accuracy of clinical staging.

Participant Demographics

The study included 34 Nigerian and 34 British women, all age-matched.

Statistical Information

P-Value

p = 0.0142 for ER, p = 0.0475 for CCND1

Confidence Interval

3.5 to 42.4

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication